riociguattal

Riociguat is a medication used to treat certain types of pulmonary hypertension. Pulmonary hypertension is a condition characterized by high blood pressure in the arteries of the lungs, which can lead to shortness of breath, fatigue, and chest pain. Riociguat is approved for the treatment of both inoperable chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH).

The drug works by stimulating an enzyme called soluble guanylate cyclase (sGC). This stimulation leads to increased levels of cyclic guanosine monophosphate (cGMP), a molecule that helps to relax and widen the blood vessels in the lungs. By reducing the pressure in these vessels, riociguat improves blood flow and alleviates the symptoms of pulmonary hypertension.

Riociguat is taken orally, typically twice a day. It is important to follow the prescribed dosage and administration instructions from a healthcare professional. Common side effects may include headache, dizziness, nausea, and vomiting. Contraindications for riociguat include co-administration with other sGC stimulators or phosphodiesterase-5 inhibitors, as this can lead to a significant drop in blood pressure. It is also not recommended for pregnant women due to potential harm to the fetus. Medical professionals will assess individual patient suitability before prescribing riociguat.